TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be 18 years old at the time the informed consent form is signed~* Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate~* Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL (1.73 nM)~* Experienced disease progression after having received at least 1 but no more than 2 prior next-generation androgen receptor-targeted therapies, and 1 prior taxane-based chemotherapy, for castration-resistant disease~* Have a deleterious mutation in BRCA1/2 or ATM, or molecular evidence of other homologous recombination deficiency~Exclusion Criteria:~* Active second malignancy, with the exception of curatively treated non-melanoma skin cancer, carcinoma in situ, or superficial bladder cancer~* Prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any platinum-based chemotherapy~* Symptomatic and/or untreated central nervous system metastases~* Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of rucaparib

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rucaparib (Type: EXPERIMENTAL): Oral rucaparib (monotherapy)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Intravenous Lidocaine on Trigeminal Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~(1) confirmed diagnosis of TN according to IASP definition, (2) age equal to or greater than 18 years, (3) visual analogue scale (VAS) score equal to or greater than 3 (out of a maximum 10), (4) DN4 score equal to or greater than 4 (out of a maximum 10), (5) having received the recommended medications for TN (antiepileptics, spasmolytics, opioids, anti-inflammatory and simple analgesic drugs) for an adequate period without therapeutic results, (6) TN duration of at least 12 months, (8) no history of allergy to lidocaine, (9) no history of substance abuse, (10) absence of severe psychiatric diseases, (11) not being pregnant, (12) not lactating, (13) absence of severe cardiac, hepatic and renal decease, and (14) be willing to provide a written informed consent to undergo the experimental procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females who are 10 - 17 years of age~* History of type 2 diabetes~* Nonsmoker~* No clinical or laboratory evidence to indicate a diagnosis of type 1 diabetes~Exclusion Criteria:~* History of diabetic ketoacidosis~* History of stroke, chronic seizures or major neurological disorder~* Consumes alcohol~* Consume more than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola or other beverages containing caffeine per day~* Unable to swallow tablets~* Has had surgery, donated or lost 1 unit of blood, or participated in another investigational study within a minimum of 4 weeks prior to starting the study~* History of multiple and/or severe allergies or has had an allergic reaction to or significant intolerability to prescription or non-prescription drugs or food~* Currently a regular user of any illicit drugs or has a history of drug or alcohol abuse~* History of clinically significant endocrine, gastrointestinal,~cardiovascular, hematological, hepatic, immunological, renal, respiratory, or~genitourinary abnormalities or diseases~* Has an estimated creatinine clearance of less than or equal to 80 mL/min

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 50 mg (Type: EXPERIMENTAL): Participants were randomized to sitagliptin 50 mg
- Sitagliptin 100 mg (Type: EXPERIMENTAL): Participants were randomized to sitagliptin 100 mg
- Sitagliptin 200 mg (Type: EXPERIMENTAL): Participants were randomized to a single dose of sitagliptin 200 mg
- Placebo to sitagliptin (Type: PLACEBO_COMPARATOR): Participants were randomized to matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of a Transversus Abdominis Plane (TAP) Block in Laparoscopic Colorectal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing elective laparoscopic colorectal resection at the Queen's Medical Centre, Nottingham~Exclusion Criteria:~* Known allergies to the local anaesthetic~* Any condition which may cause tolerance to opiates (eg chronic opioid use)~* Inability to use a PCA~* Patients less than 45kgs for whom local anaesthetic toxicity may become an issue~* Adults unable to consent for themselves

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- TAP block (Type: EXPERIMENTAL): 40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
- Standard care (Type: NO_INTERVENTION): No TAP block is given. Care is otherwise identical to arm 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Shared Decision Making for Prescription Opioids After Cesarean Delivery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Postpartum women who underwent a cesarean delivery at MGH~Exclusion Criteria:~* Non-native English speakers (identified in LMR as non-English speaking or requires interpreter)~* Women with a history of chronic opioid abuse (identified in LMR as opioid abuse or narcotic abuse)~* Chronic pain on opioids (identified in LMR as chronic pain or chronic narcotic use)~* Women on methadone or buprenorphine for treatment of opioid addiction (identified from their medication list in the LMR)~* Women with impaired decision-making abilities~* Women hospitalized for \> 7 days related to CD~* Minors (\<18 years old)~* Women being prescribed an opioid other than oxycodone during their postpartum hospitalization (identified from the MAR and discussion with rounding providers)~* Women with contraindications to taking acetaminophen or NSAIDs

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Post-cesarean delivery mothers (Type: OTHER): 1. Identify eligible women on post-operative day 3. A physician member of the study team will approach participants with study information and consent forms.~2. After informed consent is obtained, the participant will be taken through a 10 minute shared decision making session (intervention). The participant will then have the opportunity to ask questions, following which they will indicate the number of prescription opioid tablets to be discharged with (primary outcome)~3. The next contact will be at two weeks after discharge, at which time a member of the study team will contact the participant and administer a brief telephone survey with questions pertaining to perceived pain over time, pain management methods, opioid/pain medication consumption/disposal, and satisfaction with postoperative pain control.~4. A chart review will be performed by physicians in the research group on participants to gather information on demographics, indications for surgery, etc.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. acquired penile curvature \>15 and \<90 degrees associated with palpable penile plaque on physical examination~2. 1 or 2 penile plaque at screening~Exclusion Criteria:~1. taking the medication Coumadin~2. unable to achieve adequate erection with penile injection to access degree of curvature~3. undergone definitive treatment for prostate cancer, bladder cancer, or other pelvic malignancies including surgery, external beam radiation therapy, brachytherapy, cryotherapy~4. prior history of prostate cancer, hematologic disorders, chronic liver disease including cirrhosis and hepatitis C, disorders affecting the immune system, including infection with the human immunodeficiency virus, or psychiatric disorder including major depression, schizophrenia, bipolar disease~5. history of cerebrovascular accident, history of deep venous thrombosis within the past 5 years or history of untreated or severe sleep apnea~6. clinically significant abnormal lab results that would put the subject at increased risk or compromise the integrity of the study data, in the opinion of the investigator~7. received any other investigational drug within 30 days

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Injection of PMD-MSCs into the penis (Type: EXPERIMENTAL): Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based on ultrasound guided measurements of penile plaque(s) post treatment and on patient reported treatment satisfaction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Umbilical Cord Blood Transplant Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have one of the following disease types with disease-specific features as outlined in the protocol:~  * Acute myeloid leukemia (AML)~ * Acute lymphoblastic leukemia (ALL)~ * Myelodysplasia~ * Chronic myelogenous leukemia~ * Patients with aggressive non-Hodgkin's lymphoma (NHL), including diffuse large cell lymphoma, mediastinal B-cell lymphoma, transformed lymphoma, mantle cell lymphoma, and peripheral T cell lymphoma~ * Hodgkin's lymphoma~ * Relapsed Multiple Myeloma~* At least 35 days following start of preceding leukemia induction cytotoxic chemotherapy~* Patient age 18-55 years~* Karnofsky Performance status ≥ 70%~* No availability of a consenting HLA-matched related donor who is either matched fully matched or mismatched at only one locus of HLA-A, -B, and DRB1.~* No availability of a readily available HLA-matched volunteer unrelated donor (8 of 8 allele match at HLA-A, -B, -C and -DRB1). Patients with unstable disease who are in danger of significant disease progression while waiting to procure volunteer donor cells will be eligible to be treated on this protocol, even if a matched donor is available.~* Patients must have a matched or partially matched UCB unit with greater than 1.8 x10-7 nucleated cells/kg of recipient weight at the time of cryopreservation.~* No current uncontrolled bacterial, viral or fungal infection (defined as currently taking medication and progression of clinical symptoms).~* No HIV disease. Patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies.~* Non pregnant and non-nursing. Treatment under this protocol would expose a fetus to significant risks.~* Required baseline laboratory values as defined in the protocol~Exclusion Criteria:~* Symptomatic uncontrolled coronary artery disease or congestive heart failure.~* Severe hypoxemia with room air PaO2 less than 70, supplemental oxygen dependence, or DLCO less than 50 percent predicted~* Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy~* Prior allogeneic or autologous hematopoietic stem cell transplant in the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin once per day (Type: EXPERIMENTAL): 600 mg sitagliptin once per day orally starting on Day -1 for a total of 4 doses
- Sitagliptin twice per day (Type: EXPERIMENTAL): 600 mg sitagliptin twice per day orally starting on Day -1 for a total of 8 doses
- Sitagliptin three times per day (Type: EXPERIMENTAL): 600 mg sitagliptin three times per day orally starting on Day -1 for a total of 12 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients at least 18 years of age~* Constipated according to ROME I criteria~* On average, fewer than 3 satisfactory BMs per week during the observation period~* If female and of childbearing potential, patient must be surgically sterilized or using oral contraceptives, depot contraceptives, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so during the duration of study~* Are otherwise in good health, as judged by a physical examination~* In the investigator's judgment, patient is mentally competent to sign an instrument of informed consent~Exclusion Criteria:~* Patients with heme positive stool at screening. Patients with heme positive stool that can be attributed to hemorrhoids or anal fissures are eligible for inclusion.~* Patients with hypo- or hyperthyroidism as determined by history, or screening TSH results.~* Patients with known or suspected perforation or obstruction.~* History of gastric retention, inflammatory bowel disease, bowel resection, or colostomy.~* Patients with a known history of organic cause for their constipation.~* Patients meeting the ROME definition of Irritable Bowel Syndrome~* Patients currently taking any of the following medications that are known to effect bowel habits:~  * Antidiarrheals~ * Antacids containing magnesium or aluminum salts~ * Anticholinergics~ * Antispasmodic agents~ * Erythromycin and other macrolides~ * Octreotide~ * Lotronex, Zofran, or other 5-HT3 antagonists~ * Zelnorm, or other 5-HT4 agonists~ * Opiods/narcotic analgesics~ * Prokinetics~ * Serotonin re-uptake inhibitors or tricyclic antidepressants~ * Calcium antagonists~* Patients who are breastfeeding, pregnant, or intend to become pregnant during the study.~* Female patients of childbearing potential who refuse a pregnancy test.~* Patients with a known allergy to corn or polyethylene glycol.~* Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.~* Patients who, within the past 30 days have participated in an investigational clinical study~* Patients that have undergone a colonoscopy within 30 days of beginning the 14 day observation period.~* Patients that are currently taking, or have previously been treated with polyethyleneglycol3350

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Ertapenem in Patients Aged Over 75

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age\> or equal to 75 years~* Treatment with ertapenem (1g daily) for at least 48 hours IV or SC (or one then the other)~* Subject affiliated or beneficiary of a social security system,~* Free Consent, informed and signed by the participant or by the designation of a proxy if delirium and the investigator.~Exclusion Criteria:~* Age \< 75 years~* Criteria for legislation: those under protection of the justice, subject participating in other research, including a period of exclusion still going to pre-inclusion

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ertapenem IV (Type: ACTIVE_COMPARATOR): IV administration of ertapenem
- Ertapenem SC (Type: EXPERIMENTAL): SC administration of ertapenem

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants are eligible for the study if they have a diagnosis of schizophrenia, schizoaffective disorder, or bipolar I disorder and are clinically stable at the time of enrollment~  * defined as not severely depressed or acutely manic and no hospitalizations or antipsychotic medication changes in the four weeks prior to enrollment~Exclusion Criteria:~* Met criteria for a severe alcohol or substance use disorder in the last 6 months~* Met criteria for a mild alcohol or substance use disorder in the last month~* A history of head injury or neurological disease that has compromised cognitive functioning~* Ability to speak English is not sufficient to understand study procedures~* Diagnosis of learning disability, mental retardation, or pervasive developmental disorder~* Diagnosis of a medical condition that is incompatible with tDCS procedures~* Participant does not demonstrate understanding of study procedures during the consent process~* A documented history of behavioral problems that prevent participation in a group intervention~* Participated in a study of tDCS or cognitive remediation in the previous 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TDCS (Type: EXPERIMENTAL): TDCS offered concurrent with working memory focused cognitive training
- Sham (Type: SHAM_COMPARATOR): Sham stimulation offered concurrent with working memory focused cognitive training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir (TMC114/r) in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented HIV-1 infection~* Screening plasma HIV-1 RNA \>= 5000 copies/mL~* Patients qualify for treatment initiation based on the investigator's assessments and/or according to treatment guidelines~* Patients who can comply with the protocol requirements~* General medical condition, in the investigator's opinion, does not interfere with the assessments and the completion of the trial.~Exclusion Criteria:~* Presence of any currently active AIDS defining illness or receiving treatment for primary HIV infection~* Life expectancy of less than 6 months~* Previous or current use of antiretroviral medications (ARVs) for the treatment of HIV-infection or hepatitis B infection with anti-HIV activity~* Female -patients who are pregnant or breast-feeding, or are of childbearing potential without use of effective non-hormonal birth control methods or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period~* -patients with a grade 3 or 4 laboratory abnormality as defined by DAIDS grading, or a calculated creatinine clearance (CLCr) \< 70 mL/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 002 (Type: EXPERIMENTAL): TMC-114/RTV two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
- 001 (Type: ACTIVE_COMPARATOR): LPV/RTV 400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete